FranklinMChuMDFACS

Stone Disease, Surgical Oncology

President, San Bernardino Urological associates Medical Group Inc, Medical Director, San Bernardino Urology Research Center

Join to view full profile

Dr. Chu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Chu's full profile

Already have an account?

Office
489E E 21st St
San Bernardino, CA 92404
Phone+1 909-882-2973

Fax+1 909-882-2681
Is this information wrong?

Education & Training

University of California (Irvine)Residency, Urology, 1980 - 1985
University of Texas Medical Branch HospitalsInternship, Transitional Year, 1979 - 1980
Tulane University School of MedicineClass of 1979
University of Illinois at Urbana-ChampaignMS, Physical Chemitry, 1973 - 1974

Certifications & Licensure

OR State Medical License 1981 - Present
CA State Medical License 1981 - 2026
LA State Medical License 1979 - 1985
American Board of Urology Urology

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Start of enrollment: 2003 Apr 01
Completed
Phase 4
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Start of enrollment: 2006 Apr 24
Completed
Phase 3
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2013 Oct 01
Active, not recruiting
Phase 3
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC Start of enrollment: 2015 Nov 27
Active, not recruiting
Phase 3
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Start of enrollment: 2017 Jun 13
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

12 citations
Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.
Daniel Saltzstein, Neal D. Shore, Judd W. Moul, Franklin Chu, Raoul S. Concepcion, Stephan de la Motte, John A. McLane, Stuart Atkinson, Alex Yang, E. David Crawford> ;Therapeutic Advances in Urology. 2018 Feb 1
12 citations
Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with...
Neal D. Shore, Franklin Chu, Judd W. Moul, Daniel Saltzstein, Raoul S. Concepcion, John A. McLane, Stuart Atkinson, Alex Yang, E. David Crawford> ;BJU International. 2017 Feb 1
55 citations
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Mario A. Eisenberger, Alan J Koletsky, Luke T Nordquist, Roberto Pili, Nicholas J Vogelzang, Franklin M Chu> ;Clinical Cancer Research. 2015 Nov 4
12 citations
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate- resis...
Franklin Chu, Oliver Sartor, Leonard G. Gomella, Todd Rudo, Matthew C. Somerville, Belinda Hereghty, Michael J. Manyak> ;European Journal of Cancer. 2015 Aug 1
14 citations
Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer
Evan Y. Yu, Robert H. Getzenberg, Christopher C. Coss, Marc M. Gittelman, Thomas E. Keane, Ronald F. Tutrone, Laurence Belkoff, Robert Given, Joel Bass, Franklin Chu, ...> ;European Urology. 2015 Feb 1
58 citations
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
William Oh, Matthew D. Galsky, Walter M. Stadler, Sandy Srinivas, Franklin Chu, Glenn J. Bubley, J. Goddard, Joi Dunbar, Robert W. Ross> ;Urology. 2011 Sep 1
23 citations
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with doceta...
Franklin M. Chu, Joel Picus, Paula M. Fracasso, Robert Dreicer, Zhihui Lang, Brenda J. Foster> ;Investigational New Drugs. 2011 Aug 1
23 citations
Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients...
Franklin Chu, Neila Smith, Takeshi Uchida> ;Current Therapeutic Research, Clinical and Experimental. 2009 Dec 1
60 citations
Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study
Matthew R. Smith, S. Bruce Malkowicz, Franklin Chu, J. Forrest, Paul Sieber, K. Gary Barnette, Domingo Rodriquez, Mitchell S. Steiner> ;Journal of Clinical Oncology. 2008 Apr 10
84 citations
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.
Matthew R. Smith, S. B. Malkowicz, Franklin Chu, J. Forrest, David C. Price, Paul Sieber, K.G. Barnette, D. Rodriguez, Mitchell S. Steiner> ;The Journal of Urology. 2008 Jan 1
Toremifene citrate increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Smith MR, Chu F, Forrest J, Malkowicz SB, Price D, Sieber P, Barnette KG, Segal S, Steiner MS> ;J. Clin. Oncol.. 2006-06-20
55 citations
Pathophysiology of overactive bladder.
Franklin Chu, Roger R. Dmochowski> ;The American Journal of Medicine. 2006 Mar 1
49 citations
Management of overactive bladder and urge urinary incontinence in the elderly patient.
Nurum Erdem, Franklin Chu> ;The American Journal of Medicine. 2006 Mar 1
6 citations
Management of incontinence for family practice physicians.
John P. Lavelle, Mickey M. Karram, Franklin Chu, Roger R. Dmochowski, Scott MacDiarmid, David R. Staskin, Peter K. Sand, Rodney A. Appell, Nurum Erdem> ;The American Journal of Medicine. 2006 Mar 1
A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS> ;J. Urol.. 2006-02-01
28 citations
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
Franklin Chu, Roger R. Dmochowski, Daniel J. Lama, Rodney U. Anderson, Peter K. Sand> ;American Journal of Obstetrics and Gynecology. 2005 Jun 1
An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.
Sartor, O., Dineen, M.K., Perez-Marreno, R., Chu, F.M., Carron, G.J., Tyler, R.C.> ;Urology. 2003 Aug
41 citations
A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer
Ramon Perez-Marreno, Franklin M. Chu, Donald Gleason, Edward Loizides, Barton Wachs, Robert C. Tyler> ;Clinical Therapeutics. 2002 Nov 1
57 citations
A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
Franklin Chu, Maury Jayson, Martin K. Dineen, Ramon Perez, Richard C. Harkaway, Robert C. Tyler> ;The Journal of Urology. 2002 Sep 1
Necrotizing vasculitis of the penis in systemic lupus erythematosus.
Tripp BM, Chu F, Halwani F, Hassouna MM> ;J. Urol.. 1995-08-01
The giant cell lesion of jaws: neoplastic or reparative?
Leban SG, Lepow H, Stratigos GT, Chu F> ;J Oral Surg. 1971-06-01
Non-prostatic causes of acid hyperphosphatasia: report of a case due to multiple myeloma.
LEPOW H, SCHOENFELD MR, MESSELOFF CR, CHU F> ;J. Urol.. 1962-06-01
Multiple aneurysmal formation; an elastic tissue defect.
LEPOW H, CHU F, MUREN O> ;Am. J. Med.. 1958-04-01
Primary squamous-cell carcinoma of the corpus uteri.
CHU F, LEPOW H, GODSICK W> ;AMA Arch Pathol. 1958-01-01
A case of Cryptococcus neoformans meningoencephalitis complicating Boeck's sarcoid.
LEPOW H, RUBENSTEIN L, CHU F, SHANDRA J> ;Pediatrics. 1957-03-01
Join now to see all

Press Mentions

Linkin Park T-shirts Are All the Rage in ChinaJuly 9th, 2020
Clinical Investigation Site Summary: San Bernardino Urological Associates Treating Metastatic Castration Resistant Prostate CancerNovember 14th, 2019